VIVE RSI Chart
Trailing 12 Months
-100%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 6.6M | 6.8M | 6.8M | 0 |
2021 | 5.6M | 6.6M | 6.7M | 6.4M |
2020 | 4.9M | 4.5M | 5.0M | 5.5M |
2019 | 17.8M | 13.4M | 9.6M | 6.6M |
2018 | 15.9M | 18.4M | 19.1M | 18.5M |
2017 | 8.9M | 10.4M | 12.6M | 15.3M |
2016 | 2.7M | 4.2M | 5.4M | 7.1M |
2015 | 154.0K | 154.0K | 721.0K | 1.4M |
2014 | 148.4K | 144.9K | 141.3K | 163.0K |
2013 | 225.1K | 200.7K | 176.4K | 152.0K |
2012 | 565.6K | 460.2K | 354.8K | 249.4K |
2011 | 608.0K | 629.0K | 650.0K | 671.0K |
2010 | 0 | 0 | 0 | 587.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 15, 2021 | durbin scott | back to issuer | -2.8 | 1.4 | -2.00 | chief executive officer |
Dec 15, 2021 | basta steven l | back to issuer | -39.48 | 1.41 | -28.00 | - |
Dec 15, 2021 | robbins jim b | back to issuer | -51.48 | 1.43 | -36.00 | svp, finance & administration |
Oct 01, 2019 | goldman sachs group inc | sold | -131,711 | 5.56022 | -23,688 | - |
Sep 30, 2019 | goldman sachs group inc | sold | -312,753 | 4.55 | -68,737 | - |
Sep 27, 2019 | goldman sachs group inc | sold | -27,330 | 5.1 | -5,359 | - |
Sep 26, 2019 | goldman sachs group inc | sold | -36,755 | 5.25 | -7,001 | - |
Sep 25, 2019 | goldman sachs group inc | sold | -60,690 | 5.62 | -10,799 | - |
Sep 24, 2019 | goldman sachs group inc | bought | 147,768 | 5.64 | 26,200 | - |
Sep 24, 2019 | goldman sachs group inc | sold | -4,456 | 5.57 | -800 | - |
Which funds bought or sold VIVE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 14, 2024 | OLD POINT TRUST & FINANCIAL SERVICES N A | new | - | - | - | -% |
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
Unveiling Viveve Medical Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Viveve Medical Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
Revenue | -6.2% | 1,684,000 | 1,795,000 | 1,641,000 | 1,706,000 | 1,616,000 | 1,654,000 | 1,450,000 | 1,947,000 | 1,524,000 | 704,000 | 1,304,000 | 1,451,000 | 1,052,000 | 1,052,000 | 3,012,000 | 4,472,000 | 4,821,000 | 5,525,000 | 3,699,000 | 5,101,000 | 4,070,000 |
Gross Profit | 85.7% | 546,000 | 294,000 | 320,000 | -41,000 | 114,000 | 165,000 | 382,000 | 247,000 | 241,000 | -367,000 | 175,000 | -119,000 | -47,000 | 111,000 | 1,071,000 | 1,665,000 | 1,494,000 | 2,814,000 | 1,347,000 | 2,772,000 | 2,011,000 |
Operating Expenses | -2.0% | 5,208,000 | 5,314,000 | 5,793,000 | 5,946,000 | 5,606,000 | 5,110,000 | 5,511,000 | 4,570,000 | 3,645,000 | 4,574,000 | 6,002,000 | 6,934,000 | 6,481,000 | 8,432,000 | 9,848,000 | 13,933,000 | 12,556,000 | 13,109,000 | 12,687,000 | 12,201,000 | 10,833,000 |
S&GA Expenses | 0.4% | 3,408,000 | 3,393,000 | 3,653,000 | 3,085,500 | 2,911,000 | 2,930,000 | 3,581,000 | 3,190,000 | 2,761,000 | 3,350,000 | 4,365,000 | 5,175,000 | 5,032,000 | 5,530,000 | 6,626,000 | 11,187,000 | 9,114,000 | 9,437,000 | 8,931,000 | 9,150,000 | 7,369,000 |
R&D Expenses | -6.3% | 1,800,000 | 1,921,000 | 2,140,000 | 2,860,500 | 2,695,000 | 2,180,000 | 1,930,000 | 1,380,000 | 884,000 | 1,224,000 | 1,637,000 | 1,759,000 | 1,449,000 | 2,902,000 | 2,480,000 | 2,746,000 | 3,442,000 | 3,672,000 | 3,756,000 | 3,051,000 | 3,464,000 |
EBITDA Margin | 4.8% | -2.99 | -3.14 | -2.99 | -3.06 | -2.70 | -2.41 | -3.36 | -3.53 | -5.75 | -7.05 | -6.89 | -5.54 | - | - | - | - | - | - | - | - | - |
Interest Expenses | 2.8% | 292,000 | 284,000 | 270,000 | 266,000 | 255,000 | 245,000 | 234,000 | 242,000 | 235,000 | 223,000 | 210,000 | 835,000 | 1,209,000 | 1,194,000 | 1,116,000 | 1,133,000 | 1,106,000 | 1,063,000 | 1,070,000 | 784,000 | 777,000 |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | 6.9% | -4,976,000 | -5,344,000 | -5,764,000 | -6,260,000 | -5,825,000 | -3,971,000 | -5,715,000 | -4,695,000 | -3,680,000 | -7,029,000 | -6,128,000 | -14,621,000 | -7,788,000 | -9,586,000 | -9,904,000 | -13,374,000 | -12,172,000 | -11,358,000 | -12,420,000 | -10,224,000 | -9,615,000 |
EBT Margin | 4.6% | -3.27 | -3.43 | -3.30 | -3.39 | -3.03 | -2.75 | -3.75 | -3.93 | -6.31 | -7.88 | -7.85 | -6.38 | - | - | - | - | - | - | - | - | - |
Net Income | 14.2% | -4,976,000 | -5,799,000 | -5,886,000 | -6,328,000 | -5,858,000 | -4,050,000 | -5,791,000 | -4,755,000 | -3,735,000 | -7,115,000 | -6,310,000 | -14,817,000 | -7,956,000 | -9,724,000 | -10,029,000 | -13,492,000 | -12,304,000 | -11,516,000 | -12,669,000 | -10,224,000 | -9,615,000 |
Net Income Margin | 4.7% | -3.37 | -3.53 | -3.34 | -3.43 | -3.07 | -2.79 | -3.80 | -4.00 | -6.42 | -8.02 | -7.99 | -6.48 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 23.4% | -3,543,000 | -4,627,000 | -5,136,000 | -3,521,000 | -2,747,000 | -3,728,000 | -3,338,000 | -2,676,000 | -2,858,000 | -4,584,000 | -5,897,000 | -5,613,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
Assets | -21.5% | 12.00 | 15.00 | 21.00 | 26.00 | 30.00 | 34.00 | 38.00 | 17.00 | 20.00 | 21.00 | 21.00 | 27.00 | 24.00 | 25.00 | 35.00 | 47.00 | 36.00 | 49.00 | 57.00 | 36.00 | 33.00 |
Current Assets | -27.5% | 10.00 | 13.00 | 17.00 | 22.00 | 27.00 | 31.00 | 34.00 | 12.00 | 16.00 | 16.00 | 17.00 | 22.00 | 19.00 | 21.00 | 30.00 | 42.00 | 32.00 | 45.00 | 53.00 | 32.00 | 29.00 |
Cash Equivalents | -37.4% | 6.00 | 9.00 | 14.00 | 19.00 | 23.00 | 25.00 | 28.00 | 7.00 | 9.00 | 9.00 | 9.00 | 13.00 | 9.00 | 10.00 | 18.00 | 30.00 | 20.00 | 30.00 | 38.00 | 21.00 | 19.00 |
Inventory | 1.0% | 2.00 | 2.00 | 2.00 | 1.00 | 2.00 | 3.00 | 3.00 | 3.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 | 2.00 |
Net PPE | -9.4% | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 |
Liabilities | 7.4% | 11.00 | 10.00 | 11.00 | 11.00 | 10.00 | 9.00 | 10.00 | 10.00 | 9.00 | 10.00 | 9.00 | 10.00 | 39.00 | 39.00 | 39.00 | 42.00 | 39.00 | 40.00 | 38.00 | 39.00 | 26.00 |
Current Liabilities | 8.2% | 11.00 | 10.00 | 10.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 5.00 | 5.00 | 6.00 | 6.00 | 7.00 | 7.00 | 11.00 | 9.00 | 10.00 | 8.00 | 9.00 | 8.00 |
Shareholder's Equity | -77.6% | 1.00 | 5.00 | 10.00 | 15.00 | 20.00 | 25.00 | 28.00 | 7.00 | 11.00 | 11.00 | 13.00 | 17.00 | - | - | - | 5.00 | - | 9.00 | 19.00 | - | 7.00 |
Retained Earnings | -2.0% | -258 | -253 | -247 | -241 | -235 | -229 | -225 | -219 | -215 | -211 | -204 | -197 | -183 | -175 | -165 | -155 | -141 | -129 | -118 | -105 | -95.36 |
Additional Paid-In Capital | 0.3% | 260 | 259 | 258 | 257 | 256 | 255 | 253 | 227 | 226 | 222 | 217 | 214 | 168 | 161 | 161 | 160 | 139 | 138 | 137 | 103 | 102 |
Shares Outstanding | 0.3% | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 10.00 | 9.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | 31.00 | - | - | - | 9.00 | - | - | - | 18.00 | - | - | - | 68.00 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 | 2017Q3 |
Cashflow From Operations | 26.7% | -3,350 | -4,568 | -5,087 | -3,227 | -2,663 | -3,735 | -3,253 | -2,298 | -2,747 | -4,453 | -5,736 | -5,374 | -6,608 | -7,696 | -11,558 | -9,845 | -10,011 | -8,043 | -15,191 | -8,579 | -8,943 |
Share Based Compensation | -4.5% | 868 | 909 | 960 | 1,014 | 1,088 | 867 | 810 | 642 | 642 | 657 | 710 | 766 | 518 | 621 | 496 | 742 | 765 | 775 | 753 | 558 | 487 |
Cashflow From Investing | -227.1% | -193 | -59.00 | -49.00 | -294 | -84.00 | 7.00 | -85.00 | -378 | -111 | -131 | -161 | -239 | -130 | -539 | -179 | -1,159 | -180 | -341 | -462 | -95.00 | -2,910 |
Cashflow From Financing | 46.2% | 19.00 | 13.00 | 19.00 | 18.00 | 21.00 | 673 | 25,261 | -1.00 | 3,600 | 4,042 | 1,631 | 9,835 | 6,318 | -80.00 | 35.00 | 20,430 | 75.00 | 219 | 33,301 | 10,197 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue | $ 1,684 | $ 1,616 | $ 5,120 | $ 4,720 |
Cost of revenue | 1,138 | 1,502 | 3,960 | 4,059 |
Gross profit | 546 | 114 | 1,160 | 661 |
Operating expenses: | ||||
Research and development | 1,800 | 2,695 | 5,861 | 6,804 |
Selling, general and administrative | 3,408 | 2,911 | 10,454 | 9,423 |
Total operating expenses | 5,208 | 5,606 | 16,315 | 16,227 |
Loss from operations | (4,662) | (5,492) | (15,155) | (15,566) |
Gain on forgiveness of Paycheck Protection Program loan | 0 | 0 | 0 | 1,358 |
Modification of warrants | 0 | 0 | 0 | (373) |
Interest expense, net | (292) | (255) | (846) | (734) |
Other expense, net | (22) | (78) | (83) | (196) |
Net loss from consolidated companies | (4,976) | (5,825) | (16,084) | (15,511) |
Impairment loss on investment in unconsolidated limited liability company | 0 | 0 | (455) | 0 |
Loss from investment in unconsolidated limited liability company | 0 | (33) | (122) | (188) |
Comprehensive and net loss | (4,976) | (5,858) | (16,661) | (15,699) |
Series B convertible preferred stock dividends | (1,347) | (1,190) | (3,918) | (3,463) |
Net loss attributable to common stockholders | $ (6,323) | $ (7,048) | $ (20,579) | $ (19,162) |
Net loss per share of common stock: | ||||
Basic and diluted (in dollars per share) | $ (0.59) | $ (0.67) | $ (1.93) | $ (1.93) |
Weighted average shares used in computing net loss per share of common stock: | ||||
Basic and diluted (in shares) | 10,665,410 | 10,591,834 | 10,642,263 | 9,916,834 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,907,000 | $ 19,162,000 |
Accounts receivable, net of allowance for doubtful accounts of $15 and $66 as of September 30, 2022 and December 31, 2021, respectively | 860,000 | 549,000 |
Inventory | 1,615,000 | 1,472,000 |
Prepaid expenses and other current assets | 1,222,000 | 1,055,000 |
Total current assets | 9,604,000 | 22,238,000 |
Property and equipment, net | 1,009,000 | 1,554,000 |
Investment in unconsolidated limited liability company | 0 | 577,000 |
Other assets | 1,541,000 | 1,544,000 |
Total assets | 12,154,000 | 25,913,000 |
Current liabilities: | ||
Accounts payable | 1,108,000 | 1,480,000 |
Accrued liabilities | 4,101,000 | 3,053,000 |
Note payable, current portion | 5,628,000 | 0 |
Total current liabilities | 10,837,000 | 4,533,000 |
Note payable, noncurrent portion | 0 | 5,124,000 |
Other noncurrent liabilities | 133,000 | 1,190,000 |
Total liabilities | 10,970,000 | 10,847,000 |
Commitments and contingences (Note 9) | ||
Stockholders’ equity: | ||
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 10,698,857 and 10,619,846 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively | 1,000 | 1,000 |
Additional paid-in capital | 259,697,000 | 256,918,000 |
Accumulated deficit | (258,514,000) | (241,853,000) |
Total stockholders’ equity | 1,184,000 | 15,066,000 |
Total liabilities and stockholders’ equity | 12,154,000 | 25,913,000 |
Series B Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Convertible preferred stock | 0 | 0 |
Series C Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Convertible preferred stock | $ 0 | $ 0 |
 | Ms. Deborah Ann Jorn M.B.A. |
---|---|
 | viveve.com |
 | Medical Supplies |
 | 47 |